ACTRN12617001309370已完成未知
A Randomised, Double-Blind, Placebo controlled Trial Using Strategic Light exposure in the Treatment of Parkinson's Disease
The Bronowski Institute of Behavioural Neuroscience Inc0 个研究点目标入组 30 人开始时间: 2017年9月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 50 Years 至 o limit（—）
- 性别
- All
入选标准
- •A. Inclusion in the Bronowski Clinic Program for at least 4 months
- •B. Idiopathic Parkinson's disease
- •C. Receiving dopamine (DA) Replacement for at least 12 months
排除标准
- •1.Less than 12 months of responsive dopamine replacement therapy
- •2.Participation in a study of investigational or marketed drugs or devices during the 30-day period prior to the start of the study or during the study
- •3.Subjects who are medically complicated, medically unstable and/or have other severe co-morbid disease states, as determined by the investigator.
- •4.History of concurrent psychiatric illness that would preclude compliance with the protocol and/or ability to complete the study safely
- •5.History or current diagnosis of major psychiatric disorder including Bipolar I Disorder that could interfere with accurate assessment and effective treatment.
- •6.History of current or recent (within previous 12 months) alcohol, narcotic or other drug abuse by DSM-IV criteria
- •7.Active suicidal or homicidal ideation or plan, as determined by the attending clinician.
- •8.Use of light therapy treatment less than 4 months
- •9.Females of childbearing age
- •10.Currently working night shift
- •11.Planned travel outside of the state in which the trial is being conducted
- •12.Current use or use within the previous 1 month of photosensitizing or other medications including amiodarone, benoxaprofen, chlorpromazine, demeclocycline, fleroxacin, nalidixic acid, ofloxacin, piroxicam, porfimer, psoralens, quinidine, temoporfin tetracycline or oral isoretinoin (Accutane) or other remedies (St. John’s wort, melatonin)
- •13.History of significant eye trauma or disease, retinopathy, and/or cataract of a level that would significantly affect transmission or processing of light through either eye
- •14.Other neurological disorders
- •15.Pre-existing major joint problems
- •16.Any history of cerebral insult or central nervous system infection
- •17.Cognitive impairment as determined by the attending clinician.
- •18.Focal neurological deficits
- •19. Severe dyskinaesia attributable to dopamine replacement therapy or high TDB.
研究者
相似试验
撤回
2 期
Clinical trial to evaluate the effectiveness and safety of Nao Xin Qing (NXQ), a standardised herbal medicine in patients with ischaemic Stroke.Ischaemic strokeStroke - IschaemicACTRN12621000100897Western Sydney University88
已完成
2 期
Effect of Ashwagandha on the Immunity of Healthy ParticipantsCTRI/2018/07/014792Arjuna Natural Ltd24
进行中（未招募）
不适用
Clinical Trial to evaluate the efficacy, safety and tolerability of Midazolam Intranasal Spray compared with a placebo administered through the nose (intranasal) for the treatment of intermittent bouts of increased seizure in a site that monitors epilepsy.MedDRA version: 18.1Level: LLTClassification code 10015052Term: Epileptic seizureSystem Organ Class: 100000004852EpilepsyEUCTR2014-003961-49-LTpsher-Smith Laboratories, Inc.62
进行中（未招募）
不适用
Clinical Trial to evaluate the efficacy, safety and tolerability of Midazolam Intranasal Spray compared with a placebo administered through the nose (intranasal) for the treatment of intermittent bouts of increased seizure in a site that monitors epilepsy.MedDRA version: 17.1Level: LLTClassification code 10015052Term: Epileptic seizureSystem Organ Class: 100000004852EpilepsyEUCTR2014-003961-49-ITpsher-Smith Laboratories, Inc.62
进行中（未招募）
1 期
Clinical Trial to evaluate the efficacy, safety and tolerability of Midazolam Intranasal Spray compared with a placebo administered through the nose (intranasal) for the treatment of intermittent bouts of increased seizure in a site that monitors epilepsy.EpilepsyEUCTR2014-003961-49-CZpsher-Smith Laboratories, Inc.62